{"name":"Akero Therapeutics","slug":"akero","ticker":"AKRO","exchange":"NASDAQ","domain":"akerotherapeutics.com","description":"Akero Therapeutics is a biopharmaceutical company focused on developing treatments for metabolic diseases. The company's lead product, efruxolimab, is a monoclonal antibody targeting the IL-1β pathway. Akero Therapeutics is a relatively small player in the metabolic disease biotech space, but its product has shown promise in clinical trials.","hq":"South San Francisco, CA","founded":0,"employees":"","ceo":"Andrew Cheng","sector":"Metabolic Disease Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"$2.1B","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":247497000,"netIncome":-252060000,"cash":825886000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2034-06-01","label":"Efruxolimab patent cliff ($0.0B at risk)","drug":"Efruxolimab","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-28","type":"earnings","headline":"Akero Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"Akero Therapeutics reported its fourth quarter and full year 2023 financial results, with a net loss of $44.4 million for the year.","drugName":"","sentiment":"neutral"},{"date":"2023-12-14","type":"deal","headline":"Akero Therapeutics Announces $100 Million Private Placement Financing","summary":"Akero Therapeutics announced a $100 million private placement financing to support the development of its lead product, efruxolimab.","drugName":"","sentiment":"positive"},{"date":"2023-09-14","type":"trial","headline":"Akero Therapeutics Announces Positive Topline Results from Phase 2b Clinical Trial of Efruxolimab in NASH","summary":"Akero Therapeutics announced positive topline results from its Phase 2b clinical trial of efruxolimab in non-alcoholic steatohepatitis (NASH).","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi0gFBVV95cUxQMFlKSDdGMDczTFRmcV9wUUhUcGxEaW1wcE16dHlsMHZGSGdSX0tOVWpkNEFXWW5FbWdwYWRvMm9TX1BpaVk2U3VJaFBuSTB0MnFkS2V1N3ZHWUNsalduYllJczB5dDRnZ2RrSmVCYTlzNnIyaGhEbHhsWmtrNXRxVlNiRi1mekUyMkFXSWhLei0yZHo0elNtdEZEcGRJWlJZcU1aZ1ZxSE5aQkxyaThMTHozcHlPalVUbnZ6RmxaU0NRY21ZMnJudDJKR0dvYi1sZXc?oc=5","date":"2025-12-09","type":"pipeline","source":"globenewswire.com","summary":"Novo Nordisk has completed its acquisition of Akero Therapeutics - globenewswire.com","headline":"Novo Nordisk has completed its acquisition of Akero Therapeutics","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-11-08","type":"pipeline","source":"simplywall.st","summary":"Evaluating Akero Therapeutics (AKRO): Is the Current Valuation Justified After Recent Share Price Momentum? - simplywall.st","headline":"Evaluating Akero Therapeutics (AKRO): Is the Current Valuation Justified After Recent Share Price Momentum?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigAFBVV95cUxNNjVJaktsZmc4LXFoR01qTmhWSkVXczFaTEJkNUVoN0w0VjUtdWxLMW1feGZPbXRhQW04d2lLTEs5UFRlSUFUeUFvMG1HTHBTZWJla1gwUGszazNNRUpYeXowRlZFUWcySnJDcVJTUlRXQzV6UUx6ZVZadHR4M0VtbtIBhgFBVV95cUxNclhVZlgyMll2ckhRclVyTmM2MDlYSDNkWTRWVGZBb3g5MHZUcHEtT1QzYVpOdmVRbGV6NWloa2dNMGlYY2U1QWhjRkFTdEVQZXI0LVpkMEc4a1BpRF9yV1N4VkU0c0xNLWhTMUxfdWVUN2p3Mk5FTWZMcXVrLUxpeGdtMGdkQQ?oc=5","date":"2025-10-09","type":"deal","source":"cnbc.com","summary":"Novo Nordisk to buy Akero for up to $5.2 billion in new CEO's revival push - cnbc.com","headline":"Novo Nordisk to buy Akero for up to $5.2 billion in new CEO's revival push","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxQMkNXR2V5WWl6bEROTng2eHQxbDJZSGpqSWZSbnFPSGREZXpmTzlHWGpOMFc1Z3hfb3lIdXE4cmZmeXBBcjcxb3NYRTNvb1Rvb184aDNWZnVoQlJnWUtEY2gwUjRrOTlzOXhuT3dJMjk1QWtDWUQybVZvS1BYQUY2WUJfSkEyR3RyTE12d1F3OEU4c0ZMNFNv?oc=5","date":"2025-10-09","type":"deal","source":"Reuters","summary":"Novo to buy Akero for up to $5.2 billion in new CEO's revival push - Reuters","headline":"Novo to buy Akero for up to $5.2 billion in new CEO's revival push","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxNekVJaVFIREJIMjhLejA5UkVSZ21FX2h3c0g5UDlyQ3F6WGxZTDljdEZJQU1hZUtJYWU4a3p4UnNlbHE4UG9BbGZSdS1IZEQyWksxdlhLemt4bG5keE1SQjZKR21wcnk0eHFjQ1RKMDNkM2ZQUU5zaFRZQlRfanpURDFmeG1CVmtHUmdoY0dxTFpvZTJVc1E?oc=5","date":"2025-10-09","type":"deal","source":"Seeking Alpha","summary":"Novo Nordisk's Akero Deal: Panic Buy Or Wise Decision? Here's My Take (NYSE:NVO) - Seeking Alpha","headline":"Novo Nordisk's Akero Deal: Panic Buy Or Wise Decision? Here's My Take (NYSE:NVO)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxNMjRzenBVVXRseFlTdE00dUVxXzNLT1EyVWIxNWVZNG9aV3ZVWUVhc3ZvbkJYQU5mOFk0dThVekp4M0gxRnhPcGVDVnItRm5lM3p2Q1oya0JzRkJfdlljeXVMc2RvLXBKbkc4bF9heTViS0pDNVNYT0Jza3dWUlhDT3JSYzZqOFNfSFZfWTdPbnpvNm45WnVsLQ?oc=5","date":"2025-10-09","type":"pipeline","source":"The Motley Fool","summary":"Why Akero Therapeutics Stock Trounced the Market on Thursday - The Motley Fool","headline":"Why Akero Therapeutics Stock Trounced the Market on Thursday","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxOZ01mcmExdnF1MVpBT1NOcGJoNkhBRmJ1Sm1HcWtJSkEzZHBIOVFnVVZWWklQME5qeUJfNXMtNlRCTVlnWGxhQ1k5WEZCbEk3a0U3dTVJQXREMl9aalo3aFBvUnlscUktRGhQRDItdjZpbWs0dnU2SE1CakJoYkk1cnAwTGJxbnZDRWRyUmhSQWlfMXFwWVZn?oc=5","date":"2025-10-09","type":"deal","source":"Axios","summary":"Novo Nordisk agrees to acquire Akero Therapeutics - Axios","headline":"Novo Nordisk agrees to acquire Akero Therapeutics","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi7wFBVV95cUxOYkk2NW1ZbFktMjBaNE81V09HeDl0UVo3UTJsWHpRbkhvTUZ3cHdjbzV2TTc4dkoweExTSmo2eHV4LU1XVTFoak1JMHNfX2FhR19YTHBaZjBHNVY1S1Y3LTNRcWJFN282a1hZY2Z1QnVRNHJoTFBVMTFraDhtSFY5dE5qcFdEblFMUVpkZE01YjFrOGR1eHdyUzVFOUxnY1d4bXNCZDRkUW9CY05zTnVoNzBWZm9OaWlhTGN2MENFcWJxa2RSNk5CZWI1TEVwT0VkcGlsb1BpbjdYSTNDNjlhNHJGTGpQN0MxUFBYMjVmWQ?oc=5","date":"2025-10-09","type":"deal","source":"proactiveinvestors.com","summary":"Novo Nordisk acquires Akero Therapeutics and its promising liver therapy for up to $5.2B - proactiveinvestors.com","headline":"Novo Nordisk acquires Akero Therapeutics and its promising liver therapy for up to $5.2B","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxQdGxISkluaXZ2WmNSbl9BLVkxUEY2eUNTOW9TempGeElET0hYUUVra3FhN01HZGZoQ1JtVU40RWY1ZUZnLU5uSkROQlNubmlWZU41Q3VCNjBrajZybjBZMDZsRFFsdDFpNTFBeXB2MDJDRWJ1cEg2WHFrUUFtcEhGZEcyLUFvT3JoUGplU09OcEZPVkZUQ1dCUVNmUlRVNDRzeEpzXzdGS1RhZkl0X1djbzZYV21haXZ6VEln?oc=5","date":"2025-10-09","type":"deal","source":"Fast Company","summary":"Novo Nordisk to acquire Akero Therapeutics for its experimental liver disease drug - Fast Company","headline":"Novo Nordisk to acquire Akero Therapeutics for its experimental liver disease drug","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwFBVV95cUxORXBQRTZNSDgybWpZU015N3VwcHpBb1plRUFCWkkybzhXbV9mdGRPVHdKM3BvYy1YMjJqVDVpa0VMeWhNdU5ndzQ3eldmNDQ3TjJyN0NxcTNLOV9KcXcxOG1NQ0VSQi15UlpzajJIUkJUU0dtaGlUdXVrVlJ6aVFLemkwZVF5OU1WYmstUnRPUUNVNXNuSTRmeFBQNm02dHpNRFd2TTFzb3VENGM5QTREWk9FUW8zZzg?oc=5","date":"2025-10-09","type":"pipeline","source":"MedCity News","summary":"With $4.7B Akero Acquisition, Novo Nordisk Maps Out Broader Strategy in MASH and Beyond - MedCity News","headline":"With $4.7B Akero Acquisition, Novo Nordisk Maps Out Broader Strategy in MASH and Beyond","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirwFBVV95cUxPN0RqLWFxMDNUVC1nWUhBY0xTc0dWcWNTN1lrbWhkLXlJVG1TQ1pZTkJiZjd3bUdiOFFOT0dSN0hvSkJwM1c5LWxQa05xWGV6Q0pvMzd2anhkWXpyYS16RW1GcS10WjR3VE5zZzFiQTgyT1Y3S1czYkN0SEFuQ01ONVJhVDllTl84NDdpTG4tSFhOYzNTeFM1eGxldmhOZGs4UExDQ2Jvc1p1YkJWUllV?oc=5","date":"2025-08-14","type":"deal","source":"Seeking Alpha","summary":"Akero Therapeutics: Why I'm Reversing My Contrarian Buy Rating To A Contrarian Sell Rating - Seeking Alpha","headline":"Akero Therapeutics: Why I'm Reversing My Contrarian Buy Rating To A Contrarian Sell Rating","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxORGU4VXlneWFtWXpTZnYwSzdNSDVoN1RoMXJCSHE1UDExRWhvMVV5eEl4bE9STmpScHhCZW80ZS1QcXZjRjd4YlVZb0NNVjVYOWdFRVRPbzAxYk1FNDg5MXozcnFhQkV6MVVoWFdXZS1HUFVaUlhSUG5zZm5YUUdxQzhLbl9JNzlrNnRsMlNTelVSbGFpZW8zTElYMmY4SXNROGdzeGxPQWQ?oc=5","date":"2025-01-27","type":"trial","source":"Investopedia","summary":"Akero Therapeutics Stock Doubles on Liver Disease Drug Trial Results - Investopedia","headline":"Akero Therapeutics Stock Doubles on Liver Disease Drug Trial Results","sentiment":"negative"}],"patents":[{"drugName":"Efruxolimab","drugSlug":"efruxolimab","patentNumber":"","type":"Patent Cliff","expiryDate":"2034-06-01","territory":"US","annualRevenue":0}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Gilead Sciences","Novo Nordisk","Regeneron Pharmaceuticals"],"therapeuticFocus":["Metabolic Diseases","Non-Alcoholic Steatohepatitis (NASH)"],"financials":{"source":"sec_edgar+yahoo","revenue":null,"revenuePeriod":null,"revenueHistory":[],"grossProfit":null,"grossProfitHistory":[],"rdSpend":247497000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-252060000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":825886000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}